Seattle Genetics, Inc.
Records under this name other than the patents Seattle Genetics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Seattle Genetics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,345,785 | Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,428,585 | Humanized anti-CD70 binding agents and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,051,372 | Anti-CD70 antibody and its use for the treatment of cancer and immune disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,994,135 | Monomethylvaline Compounds Capable of Conjugation to Ligands Formerly held In force · High confidence | In force | High confidence | |
| US 7,964,566 | Monomethylvaline Compounds Capable of Conjugation to Ligands Formerly held In force · High confidence | In force | High confidence | |
| US 7,964,567 | Monomethylvaline Compounds Capable of Conjugation to Ligands Formerly held In force · High confidence | In force | High confidence | |
| US 8,512,707 | Methods of treating drug-resistant cancers Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,750,116 | Antibody drug conjugate metabolites Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,695,716 | Methods of treating neoplastic, autoimmune and inflammatory diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US RE45,272 | β-glucuronide-linker drug conjugates Formerly held In force · From the USPTO record | In force | From the USPTO record |